Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 3
2007 8
2009 6
2010 4
2011 8
2012 1
2013 3
2014 8
2015 16
2016 9
2017 14
2018 14
2019 11
2020 11
2021 13
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.
Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N, Casiraghi N, Susak H, Bauer K, Baumann A, John L, Seckinger A, Hose D, Müller-Tidow C, Goldschmidt H, Stegle O, Hundemer M, Weinhold N, Raab MS, Rippe K. Tirier SM, et al. Among authors: seckinger a. Nat Commun. 2021 Nov 29;12(1):6960. doi: 10.1038/s41467-021-26951-z. Nat Commun. 2021. PMID: 34845188 Free PMC article.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD. Seckinger A, et al. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2. Cancer Cell. 2017. PMID: 28262554 Free article.
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D. Seckinger A, et al. J Hematol Oncol. 2023 Dec 12;16(1):117. doi: 10.1186/s13045-023-01516-3. J Hematol Oncol. 2023. PMID: 38087365 Free PMC article.
A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.
Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI. Khoo WH, et al. Among authors: seckinger a. Blood. 2019 Jul 4;134(1):30-43. doi: 10.1182/blood.2018880930. Epub 2019 Apr 25. Blood. 2019. PMID: 31023703 Free article.
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. Fan F, et al. Among authors: seckinger a. Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18. Leukemia. 2021. PMID: 34007044 Free PMC article.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F. Stroh J, et al. Among authors: seckinger a. Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532. Blood Adv. 2022. PMID: 34768284 Free PMC article.
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.
Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin YL, Alaterre E, Jourdan M, Basbous J, Requirand G, Robert N, de Boussac H, Seckinger A, Hose D, Vincent L, Herbaux C, Constantinou A, Pasero P, Moreaux J. Ovejero S, et al. Among authors: seckinger a. Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022. Front Immunol. 2022. PMID: 36569948 Free PMC article.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau IW, Hänel M, Salwender HJ, Benner A, Raab MS, Goldschmidt H, Weinhold N. Mai EK, et al. Among authors: seckinger a. Blood Cancer J. 2023 Jan 4;13(1):1. doi: 10.1038/s41408-022-00772-9. Blood Cancer J. 2023. PMID: 36599831 Free PMC article. Clinical Trial.
126 results